Scarica l'app Stockscreener
129.47
1.46%
1.86
Precedente Chiudi:
$127.61
Aprire:
$130
Volume 24 ore:
212.30K
Relative Volume:
0.69
Capitalizzazione di mercato:
$1.85B
Reddito:
$1.30M
Utile/perdita netta:
$-41.72M
Rapporto P/E:
-34.92
EPS:
-3.7071
Flusso di cassa netto:
$-25.01M
1 W Prestazione:
+2.79%
1M Prestazione:
+4.87%
6M Prestazione:
+70.92%
1 anno Prestazione:
+442.62%
Intervallo 1D:
$123.91
$132.47
Intervallo di 1 settimana:
$117.79
$132.47
Portata 52W:
$20.20
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
129.47 | 1.85B | 1.30M | -41.72M | -25.01M | -3.7071 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella to Report Q1 Results, Host May 7 Conference Call - MyChesCo
Palvella doses first patients in angiokeratoma trial By Investing.com - Investing.com Australia
Palvella doses first patients in angiokeratoma trial - Investing.com UK
Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas - TradingView
No FDA-approved therapy exists; Palvella starts angiokeratoma study - Stock Titan
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance Singapore
Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Palvella Thrives Ahead of Q1 Figures - Baystreet.ca
Palvella Therapeutics to Host First Quarter 2026 Financial - GlobeNewswire
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 - Sahm
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap UpWhat's Next? - MarketBeat
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference - MyChesCo
Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - MSN
Certain Common Stock of Palvella Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
New Palvella Director Brings Rare Disease Insight To Low Valued Stock - Yahoo Finance
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
PVLA (Palvella Therapeutics Inc.) posts wider than expected Q4 2025 loss, shares dip 0.69% in today’s trading.Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics Appoints John D. Doux to Board - MyChesCo
Palvella to present Phase 3, Phase 2 study results at ISSVA By Investing.com - Investing.com Australia
Palvella Therapeutics (PVLA) Stock Approaches Resistance (Volatility Increases) 2026-04-20Community Breakout Alerts - Xã Thanh Hà
Palvella to present Phase 3, Phase 2 study results at ISSVA - Investing.com
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Yahoo Finance
Palvella reports 2025 results, advances QTORIN drug pipeline - MSN
Palvella Therapeutics, Inc. (PVLA): Investor Outlook and 78.86% Potential Upside in Biotech Breakthroughs - DirectorsTalk Interviews
Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo
Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com Australia
Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart
Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget
Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com
Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks
Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative
Palvella Therapeutics appoints John Doux to board of directors - Investing.com
Form 8-KCurrent report - ADVFN
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN
Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Palvella appoints McDonough as SVP of market access, patient services - MSN
PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Palvella Therapeutics (PVLA) Stock Miss Expectations | Price at $118.55, Down 1.24%Community Sell Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Singapore
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline - MyChesCo
Latest PVLA NewsPalvella Therapeutics to Present at the TD ... - Stock Titan
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):